SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as a highly speculative meme coin, triggering intense debate between traders hoping for rapid gains and community members warning of a potential rug pull due to extreme holder concentration. While some enthusiasts highlight its volatile price movements and aggressive social media promotion, many skeptics view the asset as a classic pump-and-dump scheme with no inherent utility.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is currently trending as investors react to a new shelf registration filing, sparking debate about potential financial stress versus strategic capital management. The community remains deeply divided, with some traders actively betting on a bullish breakout toward key resistance levels, while others highlight concerns over regulatory pressures, margin compression, and persistent downward price action.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing high volatility as investors weigh strong fundamental performance and AI-driven memory demand against broader geopolitical uncertainty and negative price action. While the community is divided between those frustrated by perceived institutional manipulation and others advocating for long-term accumulation, the stock's recent inclusion in the S&P 100 remains a key focal point for traders monitoring potential liquidity shifts.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending significantly higher as investors digest unconfirmed M&A rumors and high trading volume, fueling speculation about a potential buyout by a larger industry player. While the community remains divided between skepticism regarding past rumors and optimism over the company's growth, the heavy volume and aggressive price action have intensified discussions about a possible squeeze on the stock's substantial short position.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund, trading as VCX, has experienced significant volatility and massive price premiums over its net asset value since its recent IPO, with investors heavily focused on its portfolio of private AI giants like Anthropic and SpaceX. Much of the community conversation is centered on the six-month lockup period affecting early shareholders, fueling heated debates between those holding for long-term growth and others bracing for a potential price correction.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is currently trending as investors focus on the company's progress toward regulatory compliance and potential government support for deep-sea mining. The community is actively debating the significance of recent operational milestones and the impact of the upcoming TMCR listing, with many traders holding firm despite recent price volatility.

Coinbase Wrapped BTC ("cbBTC") is a token that is backed 1:1 by native Bitcoin (BTC) held by Coinbase, meaning that for all cbBTC in circulation, there is an equivalent amount of BTC held in a secure custody solution (including cold storage) provided by Coinbase. Wrapped assets, like cbBTC, are transferable tokens that are redeemable for the underlying asset. Coinbase customers can unwrap cbBTC and redeem a corresponding amount of the underlying BTC simply by depositing the cbBTC into their Coinbase accounts. cbBTC is built to be seamlessly compatible with DeFi applications, giving customers the option to tap into DeFi and unlock financial utility. cbBTC removes a key point of friction by allowing customers to use Bitcoin they already hold in new ways onchain. cbBTC is built to be seamlessly compatible with DeFi applications, so users can now tap into novel DeFi use cases like providing their Bitcoin as liquidity to DeFi protocols, using it as collateral to borrow other crypto assets, or spending it as a payment method. Wrapped assets like cbBTC are a mature concept in the crypto world, helping to bring more liquid assets onchain and facilitate an expansive financial ecosystem.

Coinbase Wrapped BTC

Investors are focused on CBBTC due to its role in yield-generating partnerships with tokens like BTCB, which provide periodic bitcoin rewards to holders. The community is actively discussing the potential of these mining collaborations and the utility of holding CBBTC within the broader Base ecosystem.

Caledonia Mining Corp. Plc engages in the exploration, development, and production of gold and other precious metals from its mineral properties. Its projects include Blanket Gold Mine and Maligreen. The company was founded on February 5, 1992 and is headquartered in St. Helier, the United Kingdom.

Caledonia Mining Corporation Plc

Caledonia Mining is trending as investors weigh strong operational performance and record gold production against the geopolitical and financial complexities of its Zimbabwean assets. Community discussion is heavily focused on the potential for massive growth once the Bilboes project reaches full production capacity, with many arguing that the market is significantly undervaluing the stock relative to its profit margins and future output.

What makes MOG an absolute game-changer is our relentless dedication to memes and viral brilliance! We don't settle for mediocrity; we plunge into the realm of sheer awesomeness! Our community is a powerhouse of meme warriors, unleashing an unstoppable onslaught of viral memes that'll leave you in awe and stitches!  We're not here to play games; we're here to dominate! MOG is all about pushing the boundaries, smashing through barriers, and leaving our competitors eating our dust! Our passion for humor burns like an inferno, and we won't rest until the entire internet bows down to our meme supremacy!  And our community? It's a brotherhood, an unyielding powerhouse of support and camaraderie! When you're part of MOG, you're part of an unstoppable force, a family forged by the fire of meme revolution!  So, if you're ready to be part of the most intense, mind-bending memecoin movement ever conceived, then buckle up, strap in, and brace yourself! MOG is here to claim the throne, and we're taking no prisoners! Get ready to witness meme history in the making!

 MOG Coin

MOG Coin is currently at the center of intense debate among investors, with some community members promoting it as a high-potential sleeper play amid potential ETF interest, while many others label it a persistent scam plagued by pump-and-dump activity. The discourse remains highly polarized, oscillating between speculation about rapid price appreciation and warnings of further downward volatility.

The Kroger Co. engages in the retail grocery business with added convenience to retail pharmacies and fuel centers. Its main focus is on growing households and increasing customer loyalty by delivering great value and convenience, and investing in four strategic pillars: Fresh, Brands, Data & Personalization and Seamless. Its brands include Big K, Smart Way, Heritage Farm, Simple Truth, and Simple Truth Organic. The company was founded by Barney Kroger in 1883 and is headquartered in Cincinnati, OH.

Kroger Co.

Kroger is trending following a positive earnings beat where stronger-than-expected e-commerce growth and pharmacy performance helped the stock maintain momentum. Investors are actively debating the company's ability to navigate current consumer spending shifts, with many focused on leadership transitions and potential impacts of ongoing merger litigation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager...

<ul class="summary-bullets"><li>If it materializes, it would be Gilead’s second major acquisition this year after it announced it would buy biotech Arcellx for $7.8 billion last month.</li><li>Ouro Medicine is developing drugs for autoimmune diseases such as lupus and rheumatoid arthritis.&nbsp;</li><li>Gilead is most known for its HIV drug franchise.</li></ul>Gilead Sciences (GILD) is reportedly looking to expand its offerings in the autoimmune disease segment with the acquisition of privately-held biotech Ouro Medicine for up to $2 billion.The Financial Times <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/81528c31-c735-41b7-b042-81a811a76877?syn-25a6b1a6=1">reported</a> on Monday that the company is looking to pay Ouro investors roughly $1.5 billion upfront in cash and at least an extra $500 million if certain clinical trial milestones are hit.As per the report, the talks are at an advanced stage and a deal could be announced in the coming days, though the terms might change. &nbsp;If it materializes, it would be Gilead’s second major acquisition this year after it announced it would buy biotech Arcellx for $7.8 billion last month in order to gain full access to a new multiple myeloma cell therapy.<h2 class="st-heading-2">Gilead’s Acquisition Approach</h2>“...we are carefully strengthening our early-stage pipeline to position Gilead well for the long term, typically investing about $1 billion annually in smaller licensing deals, partnerships, and acquisitions. Additionally, we are proactive and disciplined in our approach to later-stage acquisitions that support our strategic goals and add new growth opportunities,” the company said during its fourth quarter earnings call in February.“We're very ready, we're very proactive and disciplined, but we may not have the urgency of other companies in this sector, so we're gonna be disciplined around that. But I would say that we very much want to continue to add to our pipeline with appropriate, M&amp;A over the course of the coming years as well.”Gilead is most known for its HIV drug franchise. In 2025, the company reported a 6% in HIV product sales to $20.8 billion. The HIV product segment sales accounted for about 72% of the company’s overall product sales in the period.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around GILD stock fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.<a href="https://stocktwits.com/symbol/GILD">GILD stock</a> has gained 29% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-estee-lauder-stock-down-today/cZ3mNcjRIKb">Why Is Estee Lauder Stock Down Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Gilead Sciences logo is displayed on a smartphone screen, with the company's branding visible in the background, on April 20, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Gilead Reportedly Eyes Yet Another Acquisition Worth $2B After Arcellx Deal

The Financial Times reported on Monday that the company is looking to pay Ouro investors roughly $1.5 billion upfront in cash and at least an extra $500 million if certain clinical trial milestones are hit.

Equity

The Financial Times reported on Monday that the company is looking to pay Ouro investors roughly $1.5 billion upfront in cash and at least an extra $500 million if certain clinical trial milestones are hit.


Top Pharmaceutical Stocks Worth Watching - March 23rd

Eli Lilly and Company, AbbVie, Pfizer, Novo Nordisk A/S, Gilead Sciences, Abbott Laboratories, and Insmed are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufact...

Wealth Enhancement Advisory Services LLC Has $77.22 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Wealth Enhancement Advisory Services LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 633,185 share...

Nordea Investment Management AB Increases Position in Gilead Sciences, Inc. $GILD

Nordea Investment Management AB boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC...

New England Research & Management Inc. Buys New Stake in Gilead Sciences, Inc. $GILD

New England Research & Management Inc. bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 11,700 shares of the biopharmaceutical company's stock, v...

Top Pharmaceutical Stocks To Research - March 21st

Abbott Laboratories, AbbVie, Eli Lilly and Company, Bristol Myers Squibb, and Gilead Sciences are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool...

IAM Advisory LLC Takes $1.27 Million Position in Gilead Sciences, Inc. $GILD

IAM Advisory LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund...

BCGM Wealth Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD

BCGM Wealth Management LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 11,746 shares of the biopharmaceutical company's stock, valued at appr...

Confluence Investment Management LLC Trims Stock Position in Gilead Sciences, Inc. $GILD

Confluence Investment Management LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.5% in the 4th quarter, according to its most recent disclosure with the SEC. The...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Current Price	$137.34
Prev Close	$137.21
Open	$139.68
Dividend Yield	2.57%
50-Day Moving Average	$142.25
Beta	0.37
Avg. Volume	7.91M
PE Ratio	20.25

52-Week High	$157.29
52-Week Low	$93.37
Market Capitalization	$170.34B
EPS (Annual)	$6.78
Price to Book	7.51
Revenue Per Employee	$1.73M

GILD
Gilead Sciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GILD News

GILDGilead Sciences, Inc.